<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="T1" orientation="portrait" position="float">
 <label>Table </label>
 <caption>
  <p>Strategies for neutralizing antibody development. </p>
 </caption>
 <table frame="hsides" rules="groups">
  <thead>
   <tr>
    <th align="left" rowspan="1" colspan="1">Methods</th>
    <th align="left" rowspan="1" colspan="1">Original antibody</th>
    <th align="left" rowspan="1" colspan="1">Reformated antibody </th>
    <th align="left" rowspan="1" colspan="1">Target region</th>
    <th align="left" rowspan="1" colspan="1">In vitro/ in vivo model</th>
    <th align="left" rowspan="1" colspan="1">Ref</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="2" colspan="1">Convalescent plazma</td>
    <td align="left" rowspan="1" colspan="1">Human antibodies from convalescent COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1"> -</td>
    <td align="left" rowspan="1" colspan="1">Whole virus </td>
    <td align="left" rowspan="1" colspan="1">COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1">Duan et al. 2020; Shen et al. 2020; Xinhua 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Human antibodies from convalescent COVID-19 patients</td>
    <td align="left" rowspan="1" colspan="1"> -</td>
    <td align="left" rowspan="1" colspan="1">Whole virus </td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Wu et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Hybridoma</td>
    <td align="left" rowspan="1" colspan="1"> 47D11 Mouse/Human Chimeric full antibody against SARS-CoV</td>
    <td align="left" rowspan="1" colspan="1"> Fully human antibody</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 Spike antigen S1-S2 region</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1"> Wang et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Full antibody from mouse hybridoma </td>
    <td align="left" rowspan="1" colspan="1"> -</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 Spike antigen RBD Domain</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Xiong et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="2" colspan="1">Human hybridoma</td>
    <td align="left" rowspan="1" colspan="5">There are no NAbs developed with this technique</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Two monoclonal antibodies (P2C-1F11 and P2B-2F6) were selected from the B lymphocyte of convalescent COVID patients.</td>
    <td align="left" rowspan="1" colspan="1">The genes of the selected B lymphocytes were cloned into mammalian expression system</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 Spike antigen RBD domain</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus and SARS-CoV-2 virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Ju et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="5" colspan="1">Phage display</td>
    <td align="left" rowspan="1" colspan="1">Single-domain antibody from llama </td>
    <td align="left" rowspan="1" colspan="1"> Bivalent human IgG Fc-fusion protein</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 Spike antigen</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Wrapp et al. 2020 </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Synthetic human Fab library</td>
    <td align="left" rowspan="1" colspan="1">CDR3 Diversification by mutations </td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 Spike antigen RBD</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Zeng et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Single-domain antibody </td>
    <td align="left" rowspan="1" colspan="1">Grafting naive CDR regions into the framework region of an allele in human antibody heavy chain variable region</td>
    <td align="left" rowspan="1" colspan="1">RBD domain and the S1 subunit of SARS-CoV-2</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Wu et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Naive human scFv antibody </td>
    <td align="left" rowspan="1" colspan="1">Human IgG1 antibody (4A3)</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2 RBD</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Liu et al. 2020</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Domain library</td>
    <td align="left" rowspan="1" colspan="1">Fused with human Fc</td>
    <td align="left" rowspan="1" colspan="1">SARS-CoV-2-RBD</td>
    <td align="left" rowspan="1" colspan="1">Pseudotyped virus and SARS-CoV-2 virus neutralization assay</td>
    <td align="left" rowspan="1" colspan="1">Liu et al. 2020 </td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">Mammalian display</td>
    <td align="left" rowspan="1" colspan="5">There are no NAbs developed with this technique</td>
   </tr>
  </tbody>
 </table>
</table-wrap>
